The outlook of companies tied to Viagra's past presents a intricate investment picture . While the initial success generated substantial gains, generic alternatives have significantly eroded sales . Investing in associated pharmaceutical companies now requires a thorough assessment of proprietary safeguards, evolving healthcare shifts , and the pro